StreetAlpha
Parabilis Medicines, Inc. · Earnings

PBLS Earnings Results and History

Latest: Q3 2026From SEC 8-K, 10-Q and 10-K filingsNext report: Feb 11, 2027

Parabilis Medicines, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← PBLS stock page

Q3 2026 result
In line on EPS
  • EPS−$0.36 vs −$0.36 est 0.0%
  • Revenue–

Filed ยท Press release

Key takeaways

from the press release
  • Q3 revenue of $2.1 million came from collaboration agreements, versus no revenue a year earlier.
  • R&D rose to $45.6 million and G&A to $11.3 million as zolucatetide development and hiring expanded.
3 more takeaways with a free account.Create free account

Filings and dates

SEC EDGAR
  • Feb 11, 2027Next earnings reportexpected
  • Nov 12, 2026Earnings release, Q3 20268-K Press release

Also see PBLS institutional ownership and the earnings calendar.

PBLS earnings FAQ

What were PBLS's latest earnings?

For Q3 2026 Parabilis Medicines, Inc. reported, GAAP EPS of -$0.36. The results were filed with the SEC on Nov 12, 2026.

When is PBLS's next earnings date?

Parabilis Medicines, Inc. is expected to report on Feb 11, 2027. Dates can move until the company confirms them.

Where do these numbers come from?

Results, guidance and financials come from Parabilis Medicines, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.